Validation of claims-based algorithms for pulmonary arterial hypertension

Administrative claims studies do not adequately distinguish pulmonary arterial hypertension (PAH) from other forms of pulmonary hypertension (PH). Our aim is to develop and validate a set of algorithms using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes and electronic medical records (EMR), to identify patients with PAH. From January 2012 to August 2015, the EMRs of patients with ICD-9-CM codes for PH with an outpatient visit at the University of Texas Medical Branch were reviewed. Patients were divided into PAH or non-PAH groups according to EMR encounter diagnosis. Patient demographics, echocardiography, right heart catheterization (RHC) results, and PAH-specific therapies were assessed. RHC measurements were reviewed to categorize cases as hemodynamically determined PAH or not PAH. Weighted sensitivity, specificity, and positive and negative predictive values were calculated for the developed algorithms. A logistic regression analysis was conducted to determine how well the algorithms performed. External validation was performed at the University of Virginia Health System. The cohort for the development algorithms consisted of 683 patients with PH, PAH group (n = 191) and non-PAH group (n = 492). A hemodynamic diagnosis of PAH determined by RHC was recorded in the PAH (26%) and non-PAH (3%) groups. The positive predictive value for the algorithm that included ICD-9-CM and PAH-specific medications was 66.9% and sensitivity was 28.2% with a c-statistic of 0.66. The positive predictive value for the EMR-based algorithm that included ICD-9-CM, EMR encounter diagnosis, echocardiography, RHC, and PAH-specific medication was 69.4% and a c-statistic of 0.87. A validation cohort of 177 patients with PH examined from August 2015 to August 2016 using EMR-based algorithms yielded a similar positive predictive value of 62.5%. In conclusion, claims-based algorithms that included ICD-9-CM codes, EMR encounter diagnosis, echocardiography, RHC, and PAH-specific medications better-identified patients with PAH than ICD-9-CM codes alone.

[1]  Alexander Singer,et al.  Combining population-based administrative health records and electronic medical records for disease surveillance , 2019, BMC Medical Informatics and Decision Making.

[2]  B. Dean,et al.  Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms , 2019, Annals of the American Thoracic Society.

[3]  S. Bangalore,et al.  Cardiovascular Outcomes of Patients With Pulmonary Hypertension Undergoing Noncardiac Surgery. , 2019, The American journal of cardiology.

[4]  R. Ewert,et al.  Practical management of riociguat in patients with pulmonary arterial hypertension , 2019, Therapeutic advances in respiratory disease.

[5]  Jonathan P. Bickel,et al.  A Computable Phenotype Improves Cohort Ascertainment in a Pediatric Pulmonary Hypertension Registry , 2017, Jornal de Pediatria.

[6]  K. Dimopoulos,et al.  Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  G. Sharma,et al.  Incidence of right heart catheterization in patients initiated on pulmonary arterial hypertension therapies: A population-based study. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  S. Archer,et al.  Trends and Outcomes of Pulmonary Arterial Hypertension-Related Hospitalizations in the United States: Analysis of the Nationwide Inpatient Sample Database From 2001 Through 2012. , 2016, JAMA cardiology.

[9]  J. Fritz,et al.  The Pulmonary Hypertension Consult: Clinical and Coding Considerations. , 2016, Chest.

[10]  S. Su,et al.  Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials. , 2016, Chest.

[11]  Fabrizio Stracci,et al.  Validity of ICD-9-CM codes for breast, lung and colorectal cancers in three Italian administrative healthcare databases: a diagnostic accuracy study protocol , 2016, BMJ Open.

[12]  E. Hunsche,et al.  Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. , 2015, The American journal of managed care.

[13]  Mary G. George,et al.  Pulmonary Hypertension Surveillance , 2014, Chest.

[14]  Roderick C Deaño,et al.  Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. , 2013, JAMA internal medicine.

[15]  M. Tan,et al.  Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. , 2013, Chest.

[16]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[17]  A. Cerulli,et al.  Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States , 2012, Journal of medical economics.

[18]  Y. Lacasse,et al.  Validity of chronic obstructive pulmonary disease diagnoses in a large administrative database. , 2012, Canadian respiratory journal.

[19]  J. Gurwitz,et al.  A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data , 2012, Pharmacoepidemiology and drug safety.

[20]  Jerry H. Gurwitz,et al.  A systematic review of validated methods for identifying heart failure using administrative data , 2012, Pharmacoepidemiology and drug safety.

[21]  H. Birnbaum,et al.  Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population , 2011, Applied health economics and health policy.

[22]  J. Wild,et al.  ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre , 2011, European Respiratory Journal.

[23]  H. Birnbaum,et al.  Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States , 2011, Current medical research and opinion.

[24]  K. Chin,et al.  International Classification of Diseases coding changes lead to profound declines in reported idiopathic pulmonary arterial hypertension mortality and hospitalizations: implications for database studies. , 2011, Chest.

[25]  G. Raskob,et al.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.

[26]  A. Branzi,et al.  A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.

[27]  D. Lilienfeld,et al.  Increased mortality in African Americans with idiopathic pulmonary arterial hypertension. , 2008, Journal of the National Medical Association.

[28]  J. McMurray,et al.  An epidemiological study of pulmonary arterial hypertension , 2007, European Respiratory Journal.

[29]  George A Mensah,et al.  Pulmonary hypertension surveillance--United States, 1980-2002. , 2005, Morbidity and mortality weekly report. Surveillance summaries.

[30]  Susan O Griffin,et al.  Surveillance for dental caries, dental sealants, tooth retention, edentulism, and enamel fluorosis--United States, 1988-1994 and 1999-2002. , 2005, Morbidity and mortality weekly report. Surveillance summaries.

[31]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.